Bispecific antibodies targeting CD20xCD3 in immunotherapy for adult B-cell lymphoma: insights from the 65th American Society of Hematology 2023 annual meeting.

IF 3.6 3区医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Expert Opinion on Biological Therapy Pub Date : 2024-05-01 Epub Date: 2024-05-08 DOI:10.1080/14712598.2024.2351995

Hao Sun, Haizhou Xing, Lijie Han, Yongping Song, Zhongxing Jiang, Yanyan Liu, Jifeng Yu

引用次数: 0

Abstract

Introduction: At the 65th American Society of Hematology (ASH) 2023 Annual Meeting, the latest advancements in CD20×CD3 BsAbs for B-cell lymphoma (BCL) were highlighted, particularly in relapsed/refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL).

Areas covered: This summary highlights some of the major studies on CD20×CD3 BsAbs for BCL.

Expert opinion/commentary: CD20×CD3 is the most widely studied BsAb, with promising results in patients with R/R DLBCL and R/R FL ≥ two prior lines of systemic therapy. Trials with the first line of B-cell lymphoma also revealed promising results. Hopefully, BsAb monotherapy or BsAb-containing regimens may become the standard therapy in patients with FL and DLBCL.

查看原文本刊更多论文

针对成人 B 细胞淋巴瘤免疫疗法中 CD20xCD3 的双特异性抗体：第 65 届美国血液学会 2023 年年会的启示。

导言：在第65届美国血液学会（ASH）2023年年会上，重点介绍了CD20×CD3 BsAbs治疗B细胞淋巴瘤（BCL）的最新进展，尤其是在复发/难治性（R/R）滤泡性淋巴瘤（FL）和R/R弥漫性大B细胞淋巴瘤（DLBCL）方面：本摘要重点介绍了有关CD20×CD3 BsAbs治疗BCL的一些主要研究：CD20×CD3是目前研究最为广泛的BsAb，在R/R DLBCL和R/R FL患者中取得了令人鼓舞的结果。针对一线 B 细胞淋巴瘤的试验也显示出良好的效果。希望BsAb单药治疗或含BsAb的治疗方案能成为FL和DLBCL患者的标准疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Opinion on Biological Therapy 医学-生物工程与应用微生物

CiteScore

8.60

自引率

0.00%

发文量

审稿时长

3-8 weeks

期刊介绍： Expert Opinion on Biological Therapy (1471-2598; 1744-7682) is a MEDLINE-indexed, international journal publishing peer-reviewed research across all aspects of biological therapy. Each article is structured to incorporate the author’s own expert opinion on the impact of the topic on research and clinical practice and the scope for future development. The audience consists of scientists and managers in the healthcare and biopharmaceutical industries and others closely involved in the development and application of biological therapies for the treatment of human disease. The journal welcomes: Reviews covering therapeutic antibodies and vaccines, peptides and proteins, gene therapies and gene transfer technologies, cell-based therapies and regenerative medicine Drug evaluations reviewing the clinical data on a particular biological agent Original research papers reporting the results of clinical investigations on biological agents and biotherapeutic-based studies with a strong link to clinical practice Comprehensive coverage in each review is complemented by the unique Expert Collection format and includes the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results; Article Highlights – an executive summary of the author’s most critical points.